Monopar Therapeutics Inc. MNPR
71.97 USD -0.03 (-0.04%)
Regular-session close
71.97 0.00 0.00%
After hours · Nov 16, 4:00 PM ET
70.34 Day range 75.09
50.07 52-week range 124.82
- YTD
- +10.21%
- 1 year
- -7.73%
News
benzinga.com Morgan Stanley Maintains Overweight on Monopar Therapeutics, Raises Price Target to $133 Morgan Stanley analyst Maxwell Skor maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $130 to $133.
benzinga.com Monopar Therapeutics Q3 EPS $(0.72) Beats $(0.80) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.80) by 10 percent. This is a 50 percent decrease over losses of…
globenewswire.com Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates WILMETTE, Ill., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments…
